– Q3 total product revenue of $54.1 million, a YoY increase of 107.5%.– Q3 DAXXIFY® revenue of $22.0 million, and first full year revenue post approval of $71.0 million.– Q3 RHA® Collection revenue of $32.1 million, a YoY increase of 23.2%.– In August, DAXXIFY was approved by the FDA for the treatment of cervical dy.
Form 424B3 CNL Strategic Capital, streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.